Brokerages expect Nurix Therapeutics, Inc. (NASDAQ:NRIX) to announce ($0.43) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Nurix Therapeutics’ earnings, with estimates ranging from ($0.49) to ($0.34). The firm is scheduled to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Nurix Therapeutics will report full year earnings of ($1.57) per share for the current year, with EPS estimates ranging from ($1.90) to ($1.34). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.57) per share, with EPS estimates ranging from ($1.86) to ($1.14). Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Nurix Therapeutics.
Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Tuesday, February 16th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.02. The company had revenue of $6.69 million for the quarter, compared to the consensus estimate of $5.41 million.
NASDAQ NRIX opened at $33.62 on Monday. Nurix Therapeutics has a 52-week low of $15.21 and a 52-week high of $52.38. The company has a fifty day moving average of $35.63 and a 200-day moving average of $35.14.
In related news, CFO Houte Hans Van sold 5,330 shares of the business’s stock in a transaction dated Monday, February 22nd. The shares were sold at an average price of $39.93, for a total transaction of $212,826.90. Following the transaction, the chief financial officer now owns 1,417 shares in the company, valued at $56,580.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Christine Ring sold 2,000 shares of the business’s stock in a transaction dated Wednesday, March 10th. The shares were sold at an average price of $41.27, for a total transaction of $82,540.00. The disclosure for this sale can be found here. Insiders have sold 9,730 shares of company stock worth $386,747 in the last quarter.
Institutional investors and hedge funds have recently made changes to their positions in the business. Penserra Capital Management LLC purchased a new stake in Nurix Therapeutics in the fourth quarter worth about $29,000. Pacer Advisors Inc. grew its holdings in Nurix Therapeutics by 193.3% in the first quarter. Pacer Advisors Inc. now owns 1,581 shares of the company’s stock worth $49,000 after purchasing an additional 1,042 shares during the period. Morgan Stanley purchased a new stake in Nurix Therapeutics in the third quarter worth about $60,000. Strs Ohio purchased a new stake in Nurix Therapeutics in the third quarter worth about $97,000. Finally, Citigroup Inc. grew its holdings in Nurix Therapeutics by 559.3% in the fourth quarter. Citigroup Inc. now owns 3,514 shares of the company’s stock worth $116,000 after purchasing an additional 2,981 shares during the period. Institutional investors and hedge funds own 81.99% of the company’s stock.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Further Reading: Google Finance Portfolio Workaround
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.